The addition of oral retinoids to phototherapy has shown to enhance both the efficacy and rapidity of psoriatic lesion clearance when compared to phototherapy alone. Tazarotene is the first available topical retinoid developed for the treatment of psoriasis. In the present study, a total of 20 patients with plaque psoriasis were randomly assigned to one of the two treatment groups: tazarotene 0.1% gel plus UVB phototherapy or UVB phototherapy alone. During the two months of the study only 10 patients applied a thin film of tazarotene gel 0.1% to all psoriatic lesions once daily, in the evening. All patients were exposed to UVB three times weekly. Patients were evaluated for tolerability and global response to treatment using the Psoriasis Area and Severity Index (PASI) at days 0, 10, 20, 30, 40, 50, 60. At baseline the mean PASI in the tazarotene plus UVB group was 8.6, while in the other group it was 8.3. At the end of the study the mean PASI in the tazarotene plus UVB group was 4.6, while in the other group it was 5.4. All treatments were generally well tolerated and the incidence of undesired side effects was low.
Combination phototherapy of psoriasis with tazarotene and UVB
STINCO, Giuseppe;PATRONE, Pasquale
1999-01-01
Abstract
The addition of oral retinoids to phototherapy has shown to enhance both the efficacy and rapidity of psoriatic lesion clearance when compared to phototherapy alone. Tazarotene is the first available topical retinoid developed for the treatment of psoriasis. In the present study, a total of 20 patients with plaque psoriasis were randomly assigned to one of the two treatment groups: tazarotene 0.1% gel plus UVB phototherapy or UVB phototherapy alone. During the two months of the study only 10 patients applied a thin film of tazarotene gel 0.1% to all psoriatic lesions once daily, in the evening. All patients were exposed to UVB three times weekly. Patients were evaluated for tolerability and global response to treatment using the Psoriasis Area and Severity Index (PASI) at days 0, 10, 20, 30, 40, 50, 60. At baseline the mean PASI in the tazarotene plus UVB group was 8.6, while in the other group it was 8.3. At the end of the study the mean PASI in the tazarotene plus UVB group was 4.6, while in the other group it was 5.4. All treatments were generally well tolerated and the incidence of undesired side effects was low.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
